Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atrial Fibrillation: later-stage trial registry
60 of 204 indexed Atrial Fibrillation trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #46 of 28,707 conditions by registered trial count.
204 US clinical trials · 60 currently recruiting · #46 of 28,707 conditions by registered trial count
Atrial Fibrillation: 204 US clinical trials tracked, 60 recruiting.
Atrial Fibrillation is the subject of 204 registered US clinical trials on ClinicalTrials.gov, 60 of them currently open to new participants. 45 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is The Cleveland Clinic, running 9 of these trials.
Enrollment posture brief
Registry condition atrial-fibrillation
OPEN 60 | RECR 29% | LATE 45 | EARLY 19 | RANK #46 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Addiction (29% recruiting · 17 trials)
Atrial Fibrillation lists 60 open slots (29% of 204 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atrial Fibrillation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atrial Fibrillation is recruiting below its size-band peers.
60 of 204 indexed trials (29.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Atrial Fibrillation trials is spread across many organizations.
The Cleveland Clinic accounts for 9 of 204 trials (4.4%). 109 distinct sponsors appear on at least one study for this condition label.
-
Typical Atrial Fibrillation enrolment sits around 200 participants.
Median target enrolment is 200 among the 203 trials that report a genuine target (sentinel values excluded). 59 of those (29.1%) plan for fewer than 100 participants.
-
Atrial Fibrillation splits between interventional and observational designs.
137 interventional and 67 observational studies make up this index (67.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
204 total, page 2 of 5
Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone
University of Chicago
NCT06063538
Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study
Tulane University
NCT04814420
Use of 4D-ICE in Conjunction With TEE for Left Atrial Appendage Closure
Kansas City Heart Rhythm Research Foundation
NCT06061757
Renal Denervation + PVI vs PVI Alone for Persistent AF
University of Rochester
NCT05116384
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
Northwell Health
NCT05643235
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Tulane University
NCT05014802
Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation
Malini Madhavan
NCT04685317
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
University of South Florida
NCT02932007
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
University of Oklahoma
NCT05174052
The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study
Tulane University
NCT04947657
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Janssen Research & Development
NCT05757869
Genomic Investigation of Cardiovascular Diseases
Scripps Translational Science Institute
NCT00722748
CHAMPION-AF Clinical Trial
Boston Scientific Corporation
NCT04394546
Amplatzer Amulet LAAO vs. NOAC
Abbott Medical Devices
NCT04226547
Realtime Diagnosis From Electrocardiogram Artificial Intelligence-Guided Screening for Atrial Fibrillation With Long Follow-Up (REGAL)
Mayo Clinic
NCT05923359
SIMPLAAFY Clinical Trial
Boston Scientific Corporation
NCT06521463
Confirm Rx Insertable Cardiac Monitor SMART Registry
Abbott Medical Devices
NCT03505801
PaTH Clinical Data Research Network (CDRN) Atrial Fibrillation (AF) Clinician-Patient Partnership Cohort
University of Pittsburgh
NCT02485288
Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation
The Cleveland Clinic
NCT00599118
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
Tempus AI
NCT05442203
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
Population Health Research Institute
NCT03950076
STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation
McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT04428944
Amulet™ ADVANCE LAA
Abbott Medical Devices
NCT05997446
Acute Cognitive Changes During Atrial Fibrillation Episodes (AFCOG)
David Brunk, PA-C, MMS
NCT04033510
Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients
University of Rochester
NCT04818645
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Cortex
NCT05883631
Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF
Massachusetts General Hospital
NCT06099730
REView of ProcEdural FactoRs and Outcomes After Atrial Fibrillation Ablation With Active Esophageal COOLing: A Sub-Study of the REAL AF Registry
Heart Rhythm Clinical and Research Solutions
NCT06354777
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
University of Michigan
NCT05351749
AF at Home: A Virtual Education Program for Patients With Atrial Fibrillation (AF)
University of North Carolina, Chapel Hill
NCT05810896
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
Mina Chung, MD
NCT03603912
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
HUYABIO International
NCT04680026
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
Inova Health Care Services
NCT07250763
ECG Validation Study
Analog Device
NCT05445726
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
University of North Carolina, Chapel Hill
NCT05890274
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
University of Rochester
NCT04922281
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF
Inova Health Care Services
NCT04282850
Liraglutide Effect in Atrial Fibrillation
University of Miami
NCT03856632
Non-Invasive Median Nerve Stimulation to Attenuate Atrial Tachyarrhythmias After Catheter Ablation for Atrial Fibrillation
Icahn School of Medicine at Mount Sinai
NCT06748157
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
Brigham and Women's Hospital
NCT04593030
Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure
Bristol-Myers Squibb
NCT03508271
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
Bayer
NCT02690155
GLORIA-AF Registry Program - Second and Third Phases
Boehringer Ingelheim
NCT01468701
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Bristol-Myers Squibb
NCT00412984
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Boehringer Ingelheim
NCT00262600
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
Bayer
NCT03359876
Real-world Dosing Patterns of Rivaroxaban in the United States
Bayer
NCT03242278
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications
University of Colorado, Denver
NCT03973931
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
Sanofi
NCT00249795
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
Sanofi
NCT00249873
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 12 |
| Phase 3 | 26 |
| Phase 4 | 19 |
Top Sponsors
Named interventions
Most-linked intervention names on Atrial Fibrillation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atrial Fibrillation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atrial Fibrillation page
204 registered trials, 60 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 60 Atrial Fibrillation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- The Cleveland Clinic sponsors the most Atrial Fibrillation trials on record, review their full trial history before evaluating a specific study. See The Cleveland Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atrial Fibrillation condition card totals 204 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.